The objective of this prospective, randomized, controlled study was to test the hypothesis that central sympathetic inhibition, using the centrally acting agent moxonidine, can lead to reduced postablation recurrence risk in patients with hypertension who are undergoing pulmonary vein isolation for drug-refractory paroxysmal AF.
A utonomic system activation has increasingly been recognized as an important determinant of atrial arrhythmogenesis, 1 beyond traditional notions of vagal or adrenergic atrial fibrillation (AF). Rather than exclusively sympathetic or parasympathetic stimulation, sequential combined sympathetic and vagal activation is most commonly responsible for eliciting AF paroxysms. [2] [3] [4] Additional evidence has been provided by studies suggesting that modulation of the autonomic system, its sympathetic limb in particular, may be therapeutically useful in AF, 5, 6 by showing that suppression of the sympathetic tone leads to a significant reduction in atrial vulnerability to AF induction and postablation AF recurrence.
Our group has shown previously in a single-group crossover study that pharmacologic central sympathetic inhibition is associated with a reduction in arrhythmia burden in patients with paroxysmal AF.
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Methods
Study Population
This was a prospective, double-blinded, randomized, controlled study. The study population included hypertensive patients with symptomatic paroxysmal AF (≥2 documented episodes within the last 12 months, either self-terminating within 7 days or cardioverted in <48 hours). At least 1 episode should have been documented under treatment with a class Ic or III antiarrhythmic drug. Hypertension was defined, for the purposes of the present study, as known treated hypertension or as newly diagnosed hypertension (office arterial pressure >140/90 mm Hg in >2 measurements on 2 different days). Exclusion criteria were age <25 or >80 years, presence of atrial thrombus, left atrial diameter >49 mm, known hypersensitivity to moxonidine, sick sinus syndrome or sino-atrial block, second-or third-degree atrioventricular block, bradycardia (<50 beats per minute at rest), estimated glomerular filtration rate <40 mL/min per 1.73 m 2 , history of angioneurotic edema, heart failure symptoms or impaired left ventricular function (<40%), stable or unstable angina pectoris, intermittent claudication or known peripheral artery disease, Parkinson's disease, epileptic disorders, glaucoma, history of depression or use of antidepressants, pregnancy or lactation, and inability or unwillingness to adhere to standard treatment or to provide consent. The protocol was approved by the institutional review boards of all involved institutions. All of the patients provided informed consent.
Study Treatments
Eligible patients who provided consent were entered in a run-in period of 1 month, during which previous treatment was stabilized. One week before the scheduled ablation procedure, patients were randomly assigned to the moxonidine or the control group; the randomization process was centrally controlled from the coordinating center based on a computer-generated random number sequence (R language was used to generate the random sequence; patients were randomly assigned consecutively without applying any stratification or block scheme). Patients in the moxonidine group were started on 0.2 mg of moxonidine daily. The dose was increased to 0.4 mg daily after 3 weeks (0.2 mg twice daily), if well tolerated. Control patients received placebo, in the form of identical tablets. No class I or III antiarrhythmic drugs were allowed during the study period, with the exception of pharmacologic cardioversion in patients presenting with recurrence during the 3-month blanking period (see below).
Follow-Up and Outcome Measures
A 3-month blanking period was applied, according to current consensus. 8 Patients presenting with AF lasting for >24 hours during the blanking period were cardioverted, either pharmacologically or electrically. No repeat ablation procedures were allowed (if a patient opted for a second ablation procedure, he/she was censored at that time). The main outcome measure of the study was the time to AF recurrence after the 3-month blanking period (Kaplan-Meier analysis). Patients discontinuing the study medication or withdrawing altogether earlier than 3 months postablation were excluded from the analytic cohort. AF recurrences had to be electrocardiographically confirmed, either in rest electrocardiograms or in Holter recordings (≥30 seconds of continuous AF were required to diagnose AF recurrence in a Holter recording). Episodes of atrial flutter or other macro-re-entrant atrial tachycardia were also considered as recurrences (for the purpose of simplicity, the term "AF recurrence" will be used henceforth). Secondary outcome measures involved safety end points, including death or hospitalization for any cause, and change in the 17-item Hamilton Depression Rating Scale (HDRS-17) score between baseline and the 3-month visit.
Patients were followed on monthly clinic visits, which included full clinical and physical review, an ECG, and 48-hour ambulatory (Holter) recordings. Patients were also advised to contact the study centers and be re-evaluated at any time they might feel symptoms consistent with arrhythmia. The HDRS-17 questionnaire was filled in during an interview (study personnel with a background in psychology were responsible for this assessment) at baseline and after 3 months of study treatment. Blood pressure monitoring was based on office measurements (performed at each monthly study visit and recorded as the average of 2 measurements separated by ≥30 minutes). Patients were also instructed to perform home measurements and to record measurements in logs, which were returned to the study personnel on each study visit. These home measurements, along with 24-hour ambulatory blood pressure measurements, performed in ≈75% of patients at least once within follow-up, were used to affirm the reliability of office measurements.
Procedures and Ablation Protocol
After the run-in period, during which all of the antiarrhythmic medication was discontinued and other treatment was stabilized, patients underwent AF ablation, having started the treatment medication (moxonidine or placebo 1 week before ablation). Antral pulmonary vein isolation was performed in all of the patients. An irrigated radiofrequency ablation catheter (Thermocool, Biosense Webster, Diamond Bar, CA) was used to perform ablation, with the aid of electroanatomic mapping (Carto XP or Carto 3, Biosense Webster). Pulmonary vein potentials were recorded with a circular mapping catheter before, during, and after antral ablation (the default strategy was to create 2 ablation lines, around the 2 ipsilateral pulmonary veins, unless the left atrial anatomy dictated another approach). End point of the ablation procedure was entrance and exit block in all pulmonary veins. A waiting time of 20 to 30 minutes was observed after initial pulmonary vein isolation, and further ablation was performed in case of reconduction between the veins and the atrium. Patients with a history of documented sustained typical atrial flutter before the ablation procedure underwent additional cavotricuspid isthmus ablation. All of the patients were adequately anticoagulated during the ablation and received oral anticoagulation for 3 months after the procedure (anticoagulation thereafter was decided on according to current guidelines).
Statistical Analysis
A sample size of 148 patients per randomization group was calculated to provide 0.80 power, at a 2-sided α level of 0.05, to detect a reduction by 30% in AF recurrence hazard, assuming a mean recurrence-free survival of 6 months and an accrual time of 18 months. Kaplan-Meier analysis was performed to assess recurrence-free survival, and the log-rank test was used to make comparisons between groups (primary analysis). Continuous variables were expressed as mean±SD and compared using the t test, if their distribution did not deviate significantly from the normal (tested with the Kolmogorov-Smirnov test). If significant deviation from the Gaussian was found, nonparametric tests (MannWhitney U and Kruskal-Wallis) were applied. Categoric variables were summarized as percentages and counts and compared using the Fisher exact test. Cox regression models were created to test for independent associations of potential explanatory variables with the outcome. Continuous variables were entered as quartiles in the models. To test the effect of treatment on changes in HDRS-17 score from baseline to 3 months after ablation, ANCOVA was applied to adjust for baseline values. SPSS 17 was used (SPSS Inc, Chicago, IL) for all of the analyses. Two-sided P values of <0.05 were considered as indicative of statistical significance.
Results
From 300 consented and randomly assigned patients, after excluding 4 patients who withdrew consent to undergo pulmonary vein isolation and 5 patients who discontinued during the blanking period, 291 patients were available for Table 1 . The 2 treatment arms were equivalent in terms of basic demographics and clinical background. Overall, no significant differences in office blood pressure levels were observed between the 2 groups over the course of the study (Table 1) . Similarly, no significant differences were found in patient-reported home measurements and 24-hour ambulatory blood pressure recordings between the 2 groups (see Table I in the online-only Data Supplement). During the study follow-up (after the 3-month blanking period), recurrence was observed in 93 of 291 patients. In particular, 55 of 144 patients of the control group and 38 of 147 patients in the moxonidine group had a recurrence (unadjusted hazard ratio, 0.56 [95% CI, 0.37-0.86]; P=0.007; Kaplan-Meier estimates of 12-month recurrence rates are presented in Figure 2A ). Potential univariate correlates of recurrence are summarized in Table 2 . Patients with recurrence were older, with higher body mass index, more episodes of AF in the past year, and higher systolic blood pressure at baseline. Left atrial size and left ventricular ejection fraction were also associated with recurrence, as was left ventricular diastolic function (as indicated by the E/e′ ratio, although it should be noted that adjustment for left atrial diameter rendered this correlation nonsignificant; adjusted P=0.449). Patients with recurrence also had more radiofrequency lesions delivered during the ablation procedure (this most probably reflects a higher degree of difficulty in electrically isolating the veins, a factor obviously expected to be associated with a higher likelihood of recurrence).
In the primary outcome analysis, an early divergence of the recurrence-free survival (Kaplan-Meier) curves in the 2 treatment arms was observed ( Figure 2B ). Mean recurrencefree survival was 467 days (95% CI, 445-489 days) in the moxonidine group as compared with 409 days (95% CI, 381-437 days) in control subjects (log-rank test, P=0.006). The sensitivity of this primary outcome analysis to potential Blood pressure levels represent office measurements. For home and ambulatory blood pressure data, please refer to Table I in the online-only Data Supplement. Data are n (%) or mean±SD. ACEi indicates angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; CCB, calcium channel blocker; DBP, diastolic blood pressure; E, early peak mitral diastolic flow velocity; e′, tissue-Doppler-derived early peak velocity at the lateral mitral annulus; LA, left atrium; LV, left ventricle; RF, radiofrequency; and SBP, systolic blood pressure.
*Data are P<0.001 for the difference in systolic blood pressure between baseline and 3 mo. †Data are P <0.01 for the difference in diastolic blood pressure between baseline and 3 mo. 
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bias caused by patients who were randomly assigned but not included in the analytic cohort (9 patients in total; Figure 1 ) was tested by repeating the Kaplan-Meier analysis with the assumption that all of the excluded patients from the moxonidine group had a recurrence (at the time of exclusion), whereas all of the excluded patients from the placebo group were free of recurrence. In this analysis, the statistically significant difference in recurrence-free survival remained (log rank test, P=0.017; Figure I in the online-only Data Supplement). The effect of treatment was consistent across various clinically important subgroups, including the elderly versus younger patients (P=0.076 for the interaction between age and treatment; there was a tendency for older individuals to benefit less from treatment, but the difference did not reach statistical significance), men versus women (P=0.569), patients with high versus low body mass index (P=0.665), and diabetics versus nondiabetics (P=0.551). There was no interaction with recruiting center either (P=0.913; see Figure II in the online-only Data Supplement).
As far as secondary safety outcomes were concerned, the rate of death or hospitalization for any cause was similar in the 2 groups (2.8% in the moxonidine group versus 2.9% in the control group; 95% CI of the odds ratio, -0.24 to 3.99). The frequency potentially associated with treatment adverse effects did not differ in the 2 treatment arms, with the exception of xerostomia, which was more frequent in the moxonidine group (Table II in the online-only Data Supplement). HDRS-17 scores were similar in the 2 groups at baseline (Table 1) and showed a small decrease from baseline to 3 months (from 8.8±4.2 to 8.2±4.4; P<0.001 in the pairwise comparison in all 291 patients), without any significant differences between groups (Table 1) . After adjustment for baseline values, the difference in HDRS-17 score at 3 months between the 2 groups remained insignificant (adjusted P=0.533). Serious periprocedural complications, among the 296 patients who underwent left atrial ablation, included 3 cases (1.0%) of cardiac tamponade requiring pericardiocentesis (1 of which was further complicated by acute respiratory distress syndrome and required intubation and prolonged stay in the intensive care unit), 2 cases (0.7%) of transient cerebral ischemic attack, and 1 case (0.3%) of vascular access complication (large femoral hematoma requiring transfusions and pseudoaneurysm of the femoral artery, treated with thrombin injection). No periprocedural fatalities were recorded.
In the multivariable Cox regression analysis, randomization to moxonidine was independently associated with Data are n (%) or mean±SD. AF indicates atrial fibrillation; BMI, body mass index; DBP, diastolic blood pressure; E, early peak mitral diastolic flow velocity; e′, tissue-Doppler-derived early peak velocity at the lateral mitral annulus; LA, left atrium; LV, left ventricle; RF, radiofrequency; and SBP, systolic blood pressure.
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freedom from recurrence after adjustment for age, body mass index, number of AF episodes in the previous year, ejection fraction, left atrial diameter, number of radiofrequency lesions, and systolic blood pressure at baseline (all univariate correlates of recurrence). The adjusted hazard ratio for patients assigned to moxonidine was 0.30 (95% CI, 0.19-0.49; P<0.001). The details of this model are summarized in Table 3 . To check for overfitting, another more restrictive Cox regression model was constructed thereby eliminating covariates with significant correlations to other variables remaining in the model. This included only age, body mass index, number of AF episodes, and left atrial diameter (entered as quartiles), in addition to randomization to moxonidine. The results of this model did not differ in any substantial way from the one reported in Table 3 (adjusted  hazard ratio 
Discussion
The main finding of this prospective, randomized study was that moxonidine was associated with significantly reduced postablation AF recurrence risk, when administered to hypertensive patients undergoing pulmonary vein isolation for paroxysmal AF. The reduction in AF recurrence cannot be attributed to better control of hypertension, because blood pressure levels were similar in both treatment arms, both at baseline and over the study follow-up. The traditional approach to the role of the autonomic system in the pathophysiology of AF has focused on distinguishing between preponderantly vagal AF (most patients with idiopathic paroxysmal AF) 9 and adrenergic AF (more common in patients with heart disease). 10 However, it appears that, most commonly, a combination of sympathetic and parasympathetic overflow precedes AF paroxysms: "rather than being triggered by either vagal or sympathetic activity, the onset of AF can be associated with simultaneous discharge of both limbs," as Shen and Zipes point out in a recent review. 2 The anatomic and physiologic substrate favoring close interactions between the terminal fibers of the sympathetic and vagal systems in the heart has been known for a long time. 11 Neurotransmitters released by postganglionic axons of one limb can readily act on nerve terminals of the other, and activation of peripheral components of one elicits activity in the other (reciprocal activation and accentuated antagonism) 11, 12 ; it is, thus, difficult to imagine isolated and independent adrenergic or vagal effects in complex arrhythmias, like AF. Supporting evidence for potential clinical implications of these notions comes from several experimental and clinical studies, indicating that a primary increase in adrenergic tone followed by a marked modulation toward vagal predominance precedes episodes of paroxysmal AF, 10, [13] [14] [15] [16] both in patients with lone paroxysmal AF and in those with structural heart disease. 15 This knowledge, mainly formulated by studies conducted during the past decade, is important for potential therapeutic modalities aimed at modulation of the autonomic system: inhibition of the sympathetic limb can be expected (at least in principle) to have an effect not only in the small subset of AF patients with predominantly adrenergic AF but also in the majority of patients with paroxysmal AF.
Of note, the idea of interfering with the autonomic tone to prevent AF recurrences or to reduce arrhythmia burden goes beyond pharmacologic treatment and, in fact, has been materialized mainly in the form of various interventional treatment modalities aimed at autonomic nervous system modulation. These efforts have been principally centered on the vagal limb by locating and ablating ganglionated plexi or other structures, including the vein of Marshall. [17] [18] [19] [20] [21] [22] [23] [24] Such modalities mainly aim at interfering with imbalances in the intrinsic cardiac nervous system believed to be involved in AF pathogenesis. 25 However, interventional procedures leading to a reduction in central sympathetic activation may also be of therapeutic use. Pokushalov et al 6 showed that renal sympathetic denervation, performed in conjunction with pulmonary vein isolation, leads to less AF recurrences, and this may be construed as providing ex juvantibus evidence that sympathetic tone plays an important part in eliciting AF episodes (this hypothesis is even more plausible after recent findings that have put in doubt the effectiveness of renal denervation in inducing sustained significant reductions in arterial pressure). 26 Moxonidine is a centrally acting sympathoinhibitory agent, acting mainly through stimulation of the I1-imidazoline receptor. Moxonidine reduces the levels of central sympathetic tone, leading to significant hemodynamic and metabolic effects, with minimal stimulation of α-2 adrenergic receptors, resulting in marked reduction in undesired effects compared with older centrally acting antihypertensives, including clonidine. 27 Although moxonidine is an effective antihypertensive with favorable hemodynamic and metabolic effects, 27 in the Moxonidine in Congestive Heart Failure trial, it was found to have a deleterious effect in patients with heart failure and an ejection fraction of <35% 28 (thus the exclusion of heart failure patients from the present study). The use of moxonidine in the patient population of the present study was not associated with any 
Study Limitations
A restriction to the generalizability of the findings of the present study is the fact that the studied sample consisted of hypertensive patients. Although the blood pressure data analysis indicates that the observed differences in AF recurrence cannot be attributed to the antihypertensive action of treatment, one should be careful when extrapolating these results to nonhypertensive AF patients. Still, even if one narrowed the applicability of our observations only to hypertensive individuals, they would remain of clinical importance, given the high prevalence of hypertension in patients undergoing left atrial ablation for AF (40% to 45% in most recent studies). [29] [30] [31] In conclusion, treatment with the centrally acting sympathoinhibitory agent moxonidine is associated with less AF recurrences after ablation treatment for drug-refractory AF in patients with hypertension. The observed effect does not appear to depend on the antihypertensive action of this agent.
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